| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 9, 2004
From Vascular Biology, Department of Medicine, Division of Physiology (X.-F.M., C.B., H.V., J.R., J.-P.M., Z.Y.) and Biochemistry (S.R.), University of Fribourg; Division of Cardiology, University Hospital Geneva (B.R.K., F.M.); and Division of Hypertension and Vascular Medicine, CHUV, Lausanne (L.M., D.H.), Switzerland. * To whom correspondence should be addressed. E-mail: zhihong.yang{at}unifr.ch.
Background--Arginase competes with endothelial nitric oxide synthase (eNOS) for the substrate L-arginine and decreases NO production. This study investigated regulatory mechanisms of arginase activity in endothelial cells and its role in atherosclerosis. Methods and Results--In human endothelial cells isolated from umbilical veins, thrombin concentration- and time-dependently stimulated arginase enzymatic activity, reaching a 1.9-fold increase (P<0.001) at 1 U/mL for 24 hours. The effect of thrombin was prevented by C3 exoenzyme or the HMG-CoA reductase inhibitor fluvastatin, which inhibit RhoA, or by the ROCK inhibitors Y-27632 and HA-1077. Adenoviral expression of constitutively active RhoA or ROCK mutants enhanced arginase activity ( Conclusions--Thrombin enhances arginase activity via RhoA/ROCK in human endothelial cells. Higher arginase enzymatic activity is involved in atherosclerotic endothelial dysfunction in apoE-/- mice. Targeting vascular arginase may represent a novel therapeutic possibility for atherosclerosis.
Accepted on July 21, 2004
Thrombin Stimulates Human Endothelial Arginase Enzymatic Activity via RhoA/ROCK Pathway. Implications for Atherosclerotic Endothelial Dysfunction
Xiu-Fen Ming MD, PhD,
3-fold, P<0.001), and the effect of active RhoA mutant was inhibited by the ROCK inhibitors. Neither thrombin nor the active RhoA/ROCK mutants affected arginase II protein level, the only isozyme detectable in the cells. Moreover, a significantly higher arginase II activity (1.5-fold, not the protein level) and RhoA protein level (4-fold) were observed in atherosclerotic aortas of apoE-/- compared with wild-type mice. Interestingly, L-arginine (1 mmol/L), despite a significantly higher eNOS expression in aortas of apoE-/- mice, evoked a more pronounced contraction, which was reverted to a greater vasodilation by the arginase inhibitor L-norvaline (20 mmol/L) compared with the wild-type animals (n=5, P<0.001).
This article has been cited by other articles:
![]() |
J. A. Lang, J. D. Jennings, L. A. Holowatz, and W. L. Kenney Reflex vasoconstriction in aged human skin increasingly relies on Rho kinase-dependent mechanisms during whole body cooling Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1792 - H1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hoshino, T. Tomari, M. Nagano, N. Koshikawa, and M. Seiki A Novel Protein Associated with Membrane-type 1 Matrix Metalloproteinase Binds p27kip1 and Regulates RhoA Activation, Actin Remodeling, and Matrigel Invasion J. Biol. Chem., October 2, 2009; 284(40): 27315 - 27326. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sankaralingam, H. Xu, and S. T. Davidge Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia Cardiovasc Res, September 3, 2009; (2009) cvp277v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. N. Huynh, K. L. Andrews, G. A. Head, S. M.L. Khong, D. N. Mayorov, A. J. Murphy, G. Lambert, H. Kiriazis, Q. Xu, X.-J. Du, et al. Arginase II Knockout Mouse Displays a Hypertensive Phenotype Despite a Decreased Vasoconstrictory Profile Hypertension, August 1, 2009; 54(2): 294 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Borissoff, H. M.H. Spronk, S. Heeneman, and H. ten Cate Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res, June 1, 2009; 82(3): 392 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Rajapakse, X.-F. Ming, J. M. Carvas, and Z. Yang The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H815 - H822. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Moukdar, J. Robidoux, O. Lyght, J. Pi, K. W. Daniel, and S. Collins Reduced antioxidant capacity and diet-induced atherosclerosis in uncoupling protein-2-deficient mice J. Lipid Res., January 1, 2009; 50(1): 59 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Vanhoutte Arginine and Arginase: Endothelial NO Synthase Double Crossed? Circ. Res., April 25, 2008; 102(8): 866 - 868. [Full Text] [PDF] |
||||
![]() |
S. Ryoo, G. Gupta, A. Benjo, H. K. Lim, A. Camara, G. Sikka, H. K. Lim, J. Sohi, L. Santhanam, K. Soucy, et al. Endothelial Arginase II: A Novel Target for the Treatment of Atherosclerosis Circ. Res., April 25, 2008; 102(8): 923 - 932. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Belik, D. Shehnaz, J. Pan, and H. Grasemann Developmental changes in arginase expression and activity in the lung Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L498 - L504. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Romero, D. H. Platt, H. E. Tawfik, M. Labazi, A. B. El-Remessy, M. Bartoli, R. B. Caldwell, and R. W. Caldwell Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity Circ. Res., January 4, 2008; 102(1): 95 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Kashyap, A. Lara, R. Zhang, Y. M. Park, and R. A. DeFronzo Insulin Reduces Plasma Arginase Activity in Type 2 Diabetic Patients Diabetes Care, January 1, 2008; 31(1): 134 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kitowska, D. Zakrzewicz, M. Konigshoff, I. Chrobak, F. Grimminger, W. Seeger, P. Bulau, and O. Eickelberg Functional role and species-specific contribution of arginases in pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L34 - L45. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Deeb, R. K. Upmacis, B. D. Lamon, S. S. Gross, and D. P. Hajjar Maintaining Equilibrium by Selective Targeting of Cyclooxygenase Pathways: Promising Offensives Against Vascular Injury Hypertension, January 1, 2008; 51(1): 1 - 7. [Full Text] [PDF] |
||||
![]() |
H. K. Lim, H. K. Lim, S. Ryoo, A. Benjo, K. Shuleri, V. Miriel, E. Baraban, A. Camara, K. Soucy, D. Nyhan, et al. Mitochondrial arginase II constrains endothelial NOS-3 activity Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3317 - H3324. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Thompson-Torgerson, L. A. Holowatz, N. A. Flavahan, and W. Larry Kenney Rho kinase-mediated local cold-induced cutaneous vasoconstriction is augmented in aged human skin Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H30 - H36. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Holowatz and W. L. Kenney Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans J. Physiol., June 1, 2007; 581(2): 863 - 872. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Hamid, H. S. Bower, and G. F. Baxter Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2598 - H2606. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Horowitz, D. G. Binion, V. M. Nelson, Y. Kanaa, P. Javadi, Z. Lazarova, C. Andrekopoulos, B. Kalyanaraman, M. F. Otterson, and P. Rafiee Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease Am J Physiol Gastrointest Liver Physiol, May 1, 2007; 292(5): G1323 - G1336. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Thompson-Torgerson, L. A. Holowatz, N. A. Flavahan, and W. L. Kenney Cold-induced cutaneous vasoconstriction is mediated by Rho kinase in vivo in human skin Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1700 - H1705. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Touyz Regulation of Endothelial Nitric Oxide Synthase by Thrombin Hypertension, March 1, 2007; 49(3): 429 - 431. [Full Text] [PDF] |
||||
![]() |
K. G. Soucy, S. Ryoo, A. Benjo, H. K. Lim, G. Gupta, J. S. Sohi, J. Elser, M. A. Aon, D. Nyhan, A. A. Shoukas, et al. Impaired shear stress-induced nitric oxide production through decreased NOS phosphorylation contributes to age-related vascular stiffness J Appl Physiol, December 1, 2006; 101(6): 1751 - 1759. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Brandes Roads to Dysfunction: Argininase II Contributes to Oxidized Low-Density Lipoprotein-Induced Attenuation of Endothelial NO Production Circ. Res., October 27, 2006; 99(9): 918 - 920. [Full Text] [PDF] |
||||
![]() |
S. Ryoo, C. A. Lemmon, K. G. Soucy, G. Gupta, A. R. White, D. Nyhan, A. Shoukas, L. H. Romer, and D. E. Berkowitz Oxidized Low-Density Lipoprotein-Dependent Endothelial Arginase II Activation Contributes to Impaired Nitric Oxide Signaling Circ. Res., October 27, 2006; 99(9): 951 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hayashi, T. Esaki, D. Sumi, T. Mukherjee, A. Iguchi, and G. Chaudhuri Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism PNAS, July 5, 2006; 103(27): 10485 - 10490. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Forstermann and T. Munzel Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace Circulation, April 4, 2006; 113(13): 1708 - 1714. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Steppan, S. Ryoo, K. H. Schuleri, C. Gregg, R. K. Hasan, A. R. White, L. J. Bugaj, M. Khan, L. Santhanam, D. Nyhan, et al. Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism PNAS, March 21, 2006; 103(12): 4759 - 4764. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yang and X.-F. Ming Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res., March 1, 2006; 4(1): 53 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Andreeva, R. Vaiskunaite, M. A. Kutuzov, J. Profirovic, R. A. Skidgel, and T. Voyno-Yasenetskaya Novel Mechanisms of G Protein-Dependent Regulation of Endothelial Nitric-Oxide Synthase Mol. Pharmacol., March 1, 2006; 69(3): 975 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Loirand, P. Guerin, and P. Pacaud Rho Kinases in Cardiovascular Physiology and Pathophysiology Circ. Res., February 17, 2006; 98(3): 322 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Stanley, L. G. Chicoine, T. L. Young, K. M. Reber, C. R. Lyons, Y. Liu, and L. D. Nelin Gene transfer with inducible nitric oxide synthase decreases production of urea by arginase in pulmonary arterial endothelial cells Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L298 - L306. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. White, S. Ryoo, D. Li, H. C. Champion, J. Steppan, D. Wang, D. Nyhan, A. A. Shoukas, J. M. Hare, and D. E. Berkowitz Knockdown of Arginase I Restores NO Signaling in the Vasculature of Old Rats Hypertension, February 1, 2006; 47(2): 245 - 251. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |